M A List

Summary

Affiliation: University of Chicago
Country: USA

Publications

  1. ncbi Performance and quality of life outcome in patients completing concomitant chemoradiotherapy protocols for head and neck cancer
    M A List
    Department of Medicine, University of Chicago Cancer Research Center, IL 60637, USA
    Qual Life Res 6:274-84. 1997
  2. ncbi Quality of life and performance in advanced head and neck cancer patients on concomitant chemoradiotherapy: a prospective examination
    M A List
    Department of Medicine, Chicago Cancer Research Center, University of Chicago, IL 60637, USA
    J Clin Oncol 17:1020-8. 1999
  3. ncbi Induction chemotherapy followed by concomitant chemoradiotherapy in the treatment of locoregionally advanced oropharyngeal cancer
    C A Mantz
    Department of Cellular and Radiation Oncology, University of Chicago, Illinois 60637, USA
    Cancer J 7:140-8. 2001
  4. ncbi How Do head and neck cancer patients prioritize treatment outcomes before initiating treatment?
    M A List
    Departments of Medicine and Radiation and Cellular Oncology, and the Cancer Research Center, University of Chicago, Chicago, IL 60637, USA
    J Clin Oncol 18:877-84. 2000
  5. ncbi Evaluation of quality of life in patients definitively treated for squamous carcinoma of the head and neck
    M A List
    Department of Medicine, University of Chicago, Illinois 60637, USA
    Curr Opin Oncol 12:215-20. 2000
  6. ncbi Sequential induction chemotherapy and concomitant chemoradiotherapy in the management of locoregionally advanced laryngeal cancer
    C A Mantz
    Department of Cellular and Radiation Oncology, University of Chicago, Illinois, USA
    Ann Oncol 12:343-7. 2001
  7. ncbi Evaluations of quality of life and organ function
    Marcy A List
    University of Chicago Cancer Research Center, University of Chicago, 5841 S Maryland Avenue, Chicago, IL 60637 1470, USA
    Semin Oncol 31:827-35. 2004
  8. ncbi Single-agent versus combination chemotherapy in advanced non-small-cell lung cancer: the cancer and leukemia group B (study 9730)
    Rogerio C Lilenbaum
    The Mount Sinai Comprehensive Cancer Center, 4306 Alton Rd, Miami Beach, FL, USA
    J Clin Oncol 23:190-6. 2005
  9. ncbi Phase II trial of gefitinib 250 mg daily in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck
    Ezra E W Cohen
    Section of Hematology Oncology, Department of Medicine, University of Chicago, IL 60637, USA
    Clin Cancer Res 11:8418-24. 2005
  10. ncbi Intensity-modulated radiation therapy in advanced head and neck patients treated with intensive chemoradiotherapy: preliminary experience and future directions
    Michael T Milano
    Department of Cellular and Radiation Oncology, University of Chicago, Chicago, IL 60637, USA
    Int J Oncol 28:1141-51. 2006

Detail Information

Publications21

  1. ncbi Performance and quality of life outcome in patients completing concomitant chemoradiotherapy protocols for head and neck cancer
    M A List
    Department of Medicine, University of Chicago Cancer Research Center, IL 60637, USA
    Qual Life Res 6:274-84. 1997
    ..The data highlight the importance of systematic study of QOL dimensions and caution against making assumptions about patients' experience of particular disease and treatment sequelae...
  2. ncbi Quality of life and performance in advanced head and neck cancer patients on concomitant chemoradiotherapy: a prospective examination
    M A List
    Department of Medicine, Chicago Cancer Research Center, University of Chicago, IL 60637, USA
    J Clin Oncol 17:1020-8. 1999
    ....
  3. ncbi Induction chemotherapy followed by concomitant chemoradiotherapy in the treatment of locoregionally advanced oropharyngeal cancer
    C A Mantz
    Department of Cellular and Radiation Oncology, University of Chicago, Illinois 60637, USA
    Cancer J 7:140-8. 2001
    ..Further investigation into chemoradiotherapy as a curative modality for this disease is warranted...
  4. ncbi How Do head and neck cancer patients prioritize treatment outcomes before initiating treatment?
    M A List
    Departments of Medicine and Radiation and Cellular Oncology, and the Cancer Research Center, University of Chicago, Chicago, IL 60637, USA
    J Clin Oncol 18:877-84. 2000
    ....
  5. ncbi Evaluation of quality of life in patients definitively treated for squamous carcinoma of the head and neck
    M A List
    Department of Medicine, University of Chicago, Illinois 60637, USA
    Curr Opin Oncol 12:215-20. 2000
    ..Future challenges include the need for large multi-institutional studies, consensus about instrument selection, addressing the problem of missing data, and how to apply group OOL to individual patient decisions...
  6. ncbi Sequential induction chemotherapy and concomitant chemoradiotherapy in the management of locoregionally advanced laryngeal cancer
    C A Mantz
    Department of Cellular and Radiation Oncology, University of Chicago, Illinois, USA
    Ann Oncol 12:343-7. 2001
    ..PFL-IFN-FHX resulted in high rates of disease cure and voice preservation in a group of patients that has traditionally fared poorly in both clinical and functional outcome...
  7. ncbi Evaluations of quality of life and organ function
    Marcy A List
    University of Chicago Cancer Research Center, University of Chicago, 5841 S Maryland Avenue, Chicago, IL 60637 1470, USA
    Semin Oncol 31:827-35. 2004
    ..This article presents data on the performance, functional, and QOL results of radiation therapy (RT) and various CRT regimens in HNC...
  8. ncbi Single-agent versus combination chemotherapy in advanced non-small-cell lung cancer: the cancer and leukemia group B (study 9730)
    Rogerio C Lilenbaum
    The Mount Sinai Comprehensive Cancer Center, 4306 Alton Rd, Miami Beach, FL, USA
    J Clin Oncol 23:190-6. 2005
    ..We compared the efficacy of combination chemotherapy versus single-agent therapy in patients with advanced non-small-cell lung cancer...
  9. ncbi Phase II trial of gefitinib 250 mg daily in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck
    Ezra E W Cohen
    Section of Hematology Oncology, Department of Medicine, University of Chicago, IL 60637, USA
    Clin Cancer Res 11:8418-24. 2005
    ..This study evaluated the efficacy and toxicity of 250 mg daily gefitinib in patients with recurrent and/or metastatic SCCHN...
  10. ncbi Intensity-modulated radiation therapy in advanced head and neck patients treated with intensive chemoradiotherapy: preliminary experience and future directions
    Michael T Milano
    Department of Cellular and Radiation Oncology, University of Chicago, Chicago, IL 60637, USA
    Int J Oncol 28:1141-51. 2006
    ..Building on the present clinical experience, future directions include more directed efforts at reducing toxicity, with better planning software and planning techniques...
  11. ncbi American Society of Clinical Oncology clinical practice guideline for the use of larynx-preservation strategies in the treatment of laryngeal cancer
    David G Pfister
    American Society of Clinical Oncology, Alexandria, VA, VA 22314, USA
    J Clin Oncol 24:3693-704. 2006
    ....
  12. ncbi High survival and organ function rates after primary chemoradiotherapy for intermediate-stage squamous cell carcinoma of the head and neck treated in a multicenter phase II trial
    Ezra E W Cohen
    Section of Hematology Oncology, Department of Medicine, University of Chicago, Chicago, IL, 60637, USA
    J Clin Oncol 24:3438-44. 2006
    ..This study was undertaken to assess whether shortening treatment duration with hyperfractionated RT would be feasible and improve locoregional control, organ preservation, and progression-free survival...
  13. ncbi Functional outcomes in head and neck cancer
    Marcy A List
    University of Chicago Cancer Research Center, Chicago, IL 60637, USA
    Semin Radiat Oncol 14:178-89. 2004
    ..This article presents some of these data with a focus on the performance and functional results of radiation therapy, surgery, or concomitant chemoradiation therapy...
  14. ncbi Prioritizing treatment outcomes: head and neck cancer patients versus nonpatients
    Marcy A List
    University of Chicago Cancer Research Center, 5841 S Maryland Ave MC 1140, Chicago, Illinois 60637, USA
    Head Neck 26:163-70. 2004
    ..Understanding how patients prioritize potential outcomes, as well as whether these preferences are similar to those of nonpatients, is important to informed decision making and treatment planning...
  15. ncbi Induction chemotherapy followed by concomitant TFHX chemoradiotherapy with reduced dose radiation in advanced head and neck cancer
    Daniel J Haraf
    Department of Radiation and Cellular Oncology, University of Chicago, Chicago, Illinois 60637 1470, USA
    Clin Cancer Res 9:5936-43. 2003
    ..In an attempt to decrease toxicity without compromising local control, a second cohort of patients was treated with a lower dose of radiation to sites of potential microscopic disease...
  16. ncbi Is patient travel distance associated with survival on phase II clinical trials in oncology?
    Elizabeth B Lamont
    Department of Medicine and Cancer Research Center, The University of Chicago, Chicago, IL, USA
    J Natl Cancer Inst 95:1370-5. 2003
    ..We hypothesized that this phenomenon, often called "referral bias" or "distance bias," may also be evident in curative-intent cancer trials at specialized cancer centers...
  17. ncbi Multicenter randomized Phase II study of paclitaxel (1-hour infusion), fluorouracil, hydroxyurea, and concomitant twice daily radiation with or without erythropoietin for advanced head and neck cancer
    Fred R Rosen
    Department of Medicine, Section of Hematology/Oncology, University of Illinois at Chicago, 60637, USA
    Clin Cancer Res 9:1689-97. 2003
    ..Addition of erythropoietin does not reduce the need for transfusion with this nonplatinum-containing regimen. T-FHX should be advanced to a randomized trial and compared with a cisplatin-based concomitant regimen...
  18. ncbi Weekly carboplatin and paclitaxel followed by concomitant paclitaxel, fluorouracil, and hydroxyurea chemoradiotherapy: curative and organ-preserving therapy for advanced head and neck cancer
    Everett E Vokes
    Department of Medicine, Section of Hematology Oncology, University of Chicago IL 60637 1470, USA
    J Clin Oncol 21:320-6. 2003
    ..Locoregional and distant failure rates were 13% and 23%, respectively. To reduce distant failure rates, we added a brief course of induction chemotherapy to TFHX...
  19. ncbi An exploration of the pretreatment coping strategies of patients with carcinoma of the head and neck
    Marcy A List
    Department of Medicine, University of Chicago, Chicago, Illinois 60637, USA
    Cancer 95:98-104. 2002
    ..Understanding how patients cope with these challenges is important in comprehensive care of patients with HNC...
  20. ncbi Characteristics associated with swallowing changes after concurrent chemotherapy and radiotherapy in patients with head and neck cancer
    Joseph K Salama
    Department of Radiation and Cellular Oncology, 5758 S Maryland Ave, MC 9006, Chicago, IL 60637, USA
    Arch Otolaryngol Head Neck Surg 134:1060-5. 2008
    ..To define factors that acutely influenced swallowing function prior to and during concurrent chemotherapy and radiotherapy...
  21. ncbi Quality of life and late toxicities in head and neck cancer
    Marcy A List
    University of Chicago Cancer Research Center, Chicago, IL 60637, USA
    Cancer Treat Res 114:331-51. 2003